Rare clinical observation of pronounced response to immunotherapy in a patient with anaplastic thyroid cancer

Cover Page

Cite item

Full Text

Abstract

Anaplastic thyroid cancer is the rarest and the most aggressive form of thyroid cancer. It comprises 1-2 % of all cases and is characterized by rapid growth. median survival of patients with this pathology is about 5 months. Clinical manifestations of the disease are rapid deformation in the neck area, progressive respiratory distress, and dysphagia.

The article describes a clinical case of a response of unresectable, BRAF-negative, PD-L1-positive (programmed death-ligand 1) anaplastic thyroid cancer to immunotherapy with pembrolizumab.

About the authors

D. M. Vontlaya

Multidisciplinary clinical medical center “Medical city”

Author for correspondence.
Email: mirhaleeva@mail.ru

Dinara M. Vontlaya.

32 Barnaul'skaya St., Tyumen 625000

Russian Federation

O. V. Stryapikhina

Tyumen State Medical University, Ministry of Health of Russia

54 Odesskaya St., Tyumen 625023

Russian Federation

A. A. Egorin

Multidisciplinary clinical medical center “Medical city”

ORCID iD: 0000-0002-1126-6133

32 Barnaul'skaya St., Tyumen 625000

Russian Federation

A. V. Logvinenko

Multidisciplinary clinical medical center “Medical city”

32 Barnaul'skaya St., Tyumen 625000

Russian Federation

R. I. Tamrazov

Multidisciplinary clinical medical center “Medical city”

ORCID iD: 0000-0002-6831-6971

32 Barnaul'skaya St., Tyumen 625000

Russian Federation

References

  1. Luk'yanov S.A., Sergiyko S.V., Titov S.E. et al. New opportunities for preoperative diagnosis of anaplastic thyroid cancer. Opukholi golovy i shei = Head and Neck Tumors 2021;11(1):34-40. (In Russ.). doi: 10.17650/2222-1468-2021-11-1-34-40
  2. Pylev A.L., Zhandarova A.A., Petrov K.S. et al. Anaplastic thyroid cancer. Is there a light at the end of the tunnel? Opukholi golovy i shei = Head and Neck Tumors 2020;10(1):10-9. (In Russ.). doi: 10.17650/2222-1468-2020-10-1-10-19
  3. Nikiforovich P.A., Rumyantsev P.O., Sleptsov I.V. et al. Treatment of BRAFV600E-positive anaplastic thyroid carcinoma: case report. Sibirskiy onkologicheskiy zhurnal = Siberian Journal of Oncology журнал 2020;19(5):131-44. (In Russ.). doi: 10.21294/1814-4861-2020-19-5-131-144
  4. Mudunov A.M., Pheshkhova B.G., Zeynalova P.A. et al. The difficulties of diagnosis and features of the clinical course of anaplastic thyroid cancer. A clinical case. MD-Onco 2022;2(4):22-6. (In Russ.). doi: 10.17650/2782-3202-2022-2-4-22-26
  5. Samsonov R., Burdakov V., Shtam T. et al. Plasma exosomal miR-21 and miR-181a differentiates follicular from papillary thyroid cancer. Tumour Biol 2016;37(9):12011-21. doi: 10.1007/s13277-016-5065-3
  6. Volante M., Lam A.K., Papotti M. et al. Molecular pathology of poorly differentiated and anaplastic thyroid cancer: what do pathologists need to know? Endocr Pathol 2021;32(1):63-76. doi: 10.1007/s12022-021-09665-2
  7. Santhanam P., Khthir R., Solnes L.B., Ladenson P.W. The relationship of BRAFv600e mutation status to FDG PET/CT avidity in thyroid cancer: a review and meta-analysis. Endocr Pract 2018;24(1):21-6. doi: 10.4158/EP-2017-0080
  8. FDA approves dabrafenib plus trametinib for anaplastic thyroid cancer with BRAFV600E mutation. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-dabrafenibplus-trametinib-anaplastic-thyroid-cancer-braf-v600e-mutation.
  9. Naing A., Gainor J.F., Gelderblom H. et al. A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors. J Immunother Cancer 2020;8(1):e000530. doi: 10.1136/jitc-2020-000530
  10. Cabanillas M.E., Dadu R., Iyer P. et al. Acquired secondary RAS mutation in BRAFV600E-mutated thyroid cancer patients treated with BRAF inhibitors. Thyroid 2020;30(9):1288-96. doi: 10.1089/thy.2019.0514
  11. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12(4):252-64.
  12. Edwards S.C., Hoevenaar W.H.M., Coffelt S.B. Emerging immunotherapies for metastasis. Br J Cancer 2021;124(1):37-48. doi: 10.1038/s41416-020-01160-5
  13. Larkin J., Chiarion-Sileni V., Gonzalez R. et al. Combined nivolumab and ipilimumab or monotherapy in previously untreated melanoma. N Engl J Med 2015;373(1):23-34. doi: 10.1056/NEJMoa1504030
  14. Borel C., Jung A.C., Burgy M. Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Cancer 2020;12(9):2691. doi: 10.3390/cancers12092691

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Vontlaya D.M., Stryapikhina O.V., Egorin A.A., Logvinenko A.V., Tamrazov R.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36990 от  21.07.2009.